Coatue Management Adds $20M in Intuitive Surgical, Inc. ($ISRG)

Coatue Management recently boosted its position in Intuitive Surgical, Inc. (NasdaqGS: ISRG) by adding 47,991 shares. This increase brought its total holdings to 855,225 shares, representing a 5.9% rise. The value of Coatue's stake in the company is now approximately $351.5 million, according to the latest filing with the SEC for the quarter ending March 31, 2026.

What Changed in Coatue Management's Intuitive Surgical Position

Coatue Management increased its investment in Intuitive Surgical by 47,991 shares, moving from 807,234 shares previously to 855,225 shares. This 5.9% increase reflects Coatue's confidence in the company's prospects, with the total holding now valued at about $351.5 million.

Other Institutional Activity in Intuitive Surgical

In related institutional activity, BlackRock, Inc. reduced its position by 440,248 shares, leaving it with 30,075,905 shares valued at approximately $13.86 billion. Vanguard Capital Management LLC maintained its holdings steady at 23,079,490 shares, valued at about $10.64 billion. State Street Corp added 145,382 shares, resulting in a total of 15,846,973 shares worth $7.31 billion. Meanwhile, Geode Capital Management, LLC increased its holdings by 241,160 shares, now holding 8,466,851 shares valued at $3.89 billion.

Intuitive Surgical Stock Snapshot

Shares of Intuitive Surgical traded around $411.06. The company, with a market cap of about $145.6 billion, has a P/E ratio of 50.0 and a forward P/E ratio of 34.9. Its beta stands at 1.453, indicating higher volatility compared to the market. The stock's 52-week range is between $396.68 and $603.88, with moving averages of $444.35 over 50 days and $492.23 over 200 days.

Recent Earnings

Intuitive Surgical reported revenue of approximately $10.58 billion, with a growth rate of 23%. The company's net margin is 28.2%, and it achieved a return on equity of 17.2%. The next earnings report is scheduled for April 21, 2026.

Insider Buying and Selling at Intuitive Surgical, Inc.

Recent insider transactions at Intuitive Surgical included planned sales by Mark Brosius, EVP & Chief Manufacturing and Supply Chain Officer, who sold 25 shares on June 12, 2026, at an average price of $414.13. CEO David Rosa also sold shares, including 674 shares at $426.61 on June 10, 2026, but also acquired 1,358 shares on the same day.

Analysts Set New Price Targets

On May 18, 2026, B of A Securities maintained its buy rating for Intuitive Surgical with a price target of $520. Barclays, on April 23, 2026, reiterated its buy rating with a target of $651. Other firms like Leerink Partners, Baird, and Piper Sandler also maintained buy ratings with targets ranging from $573 to $610. The consensus among 29 analysts is a buy rating, with an average target price of $565.25.

About Intuitive Surgical

Intuitive Surgical, Inc. is a healthcare company based in Sunnyvale, California. It develops and markets products that enhance the quality of minimally invasive care. The company's flagship product, the da Vinci Surgical System, allows for robotic-assisted surgeries. It also offers the Ion endoluminal system for minimally invasive lung biopsies. Led by CEO David J. Rosa, Intuitive Surgical employs over 17,000 people and serves a global market.

Bottom Line

Coatue Management's recent increase in Intuitive Surgical shares underscores its confidence in the company's future. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings are historical and don't necessarily reflect current positions. Intuitive Surgical continues to be a significant player in the medical instruments sector, with strong institutional support and favorable analyst ratings.